A Study of Neoadjuvant Tislelizumab With SBRT in Patients With Resectable Hepatocellular Carcinoma

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Hepatocellular Carcinoma

Interventions

COMBINATION_PRODUCT

PD-1 plus stereotactic body radiotherapy

neoadjuvant PD-1(Tislelizumab) plus stereotactic body radiotherapy (8 Gy × 3 fractions) in resectable HCC

Trial Locations (1)

Shandong Cancer Hospital and Institute, Jinan